Catabasis raises $32M to advance hypertriglyceridemia drug

11/18/2013 | American City Business Journals

Catabasis Pharmaceuticals has raised $32 million in its latest funding round and hired former JSB-Partners adviser Ian Sanderson to become its new chief financial officer. The Cambridge, Mass.-based firm said the money will be used for the midstage trials of its hypertriglyceridemia drug candidate CAT-2003.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY